South Korean medical experts are urging people who repeatedly forget familiar names or words, lose track of parts of conversations, or say the same thing over and over to consider whether the problem is mild cognitive impairment rather than simple forgetfulness, according to a report by 미디어데일.
The condition is easy to overlook because people who have it generally manage daily life without major difficulty, the outlet reported on October 8, citing the medical community. That preserved independence is precisely why many cases go unaddressed.
Why it matters
Mild cognitive impairment occupies the ground between normal aging and dementia. According to 미디어데일, patients with the condition face a substantially higher risk of developing dementia than older adults in general, and some research indicates that about 10 to 15 percent of them progress to dementia each year.
That annual conversion rate makes early identification important. The same reporting notes that some people with mild cognitive impairment may already be in the early stages of Alzheimer's disease, the most common cause of dementia, which gives a diagnosis added significance.
What defines the condition
Mild cognitive impairment describes a state in which cognitive abilities, memory included, have declined noticeably while the person retains the capacity to carry out daily activities independently, according to the report. The decline cannot rest on a patient's own sense that something is wrong. It must also be confirmed through objective testing.
Because the condition can overlap with other psychiatric problems such as delirium or depression, 미디어데일 reported that an accurate diagnosis from a specialist is required.
The symptoms are not limited to memory. The report describes a fairly clear decline in cognitive function, with memory problems such as failing to recall parts of a conversation or repeating statements standing out as typical. In other cases, memory loss is less prominent and language difficulties come first, such as struggling to bring names or words to mind. Some patients experience a weakened sense of direction, find navigation somewhat harder, or show changes in visuospatial ability before other cognitive functions decline.
How doctors reach a diagnosis
Evaluation begins with neuropsychological testing to document objective cognitive decline, according to the report. Blood tests and imaging such as brain MRI are then used to distinguish among possible causes.
Amyloid positron emission tomography, or amyloid PET, can reveal whether a patient has Alzheimer's disease even at the mild cognitive impairment stage. The scan measures how much beta-amyloid protein, one of the core pathologies of Alzheimer's, has accumulated in the brain, 미디어데일 reported.
Treatment and risk management
Management of mild cognitive impairment centers on identifying the cause and controlling modifiable risk factors to lower the chance of progression to dementia, according to the report.
The lifestyle measures cited include regular exercise, a balanced diet with fish and vegetables, and staying socially connected with other people. Keeping the brain active through frequent reading and writing is also described as helpful. The report adds that actively managing high blood pressure, diabetes and high cholesterol, along with limiting alcohol and quitting smoking, matters as well.
Drug treatment for mild cognitive impairment was once limited, but that has shifted. When amyloid PET and other tests confirm Alzheimer's disease, anti-amyloid antibody therapy can now slow cognitive decline and delay progression to dementia, according to the report.
Kim Min-jae, a professor of psychiatry at Soonchunhyang University Seoul Hospital, told 미디어데일 that patients with mild cognitive impairment are at high risk of progressing to dementia, but not all of them do. He said that because treatment options now exist to confirm Alzheimer's pathology at the mild cognitive impairment stage and slow the disease through antibody therapy, making an accurate diagnosis early has become more important than before.
What to watch: whether testing rates for amyloid PET and other diagnostic tools rise in South Korea, and how widely anti-amyloid antibody therapy becomes available to patients diagnosed at this earlier stage.
